Merck reported second-quarter revenue surpassing Wall Street expectations, driven by strong sales of its cancer drug Keytruda and other treatments. Adjusted earnings per share also exceeded expectations. The company raised its full-year sales forecast slightly but lowered its profit guidance due to acquisition charges. Keytruda sales rose 16, while sales for its HPV vaccine were nearly flat. The newly launched Winrevair and Capvaxive showed promising starts.